{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:31:15Z","timestamp":1784237475563,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Advanced ovarian cancer (AOC) and its treatment cause several symptoms and impact on patients\u2019 health-related quality of life (HRQoL). We aim to reach a consensus on the most relevant patient-reported outcome (PROs), the corresponding measures (PROMs), and measurement frequency during AOC patients\u2019 follow-up from patients\u2019 and healthcare professionals\u2019 (HCP) perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The project comprised five steps: 1) a literature review, 2) a focus group with patients, 3) a nominal group with HCP, 4) two round-Delphi consultations with patients and HCP, and 5) a final meeting with HCP. Delphi questionnaire was elaborated based on literature review, focus group (n=5 patients), and nominal group (n=16 HCP). The relevance of each PRO and the appropriateness (A) and feasibility (F) of the proposed PROM were assessed (Likert scale 1=strongly agree; 9=strongly disagree). The consensus was reached when at least 75% of the panelists rated it as \u2018relevant\u2019, \u2018appropriate\u2019, or \u2018feasible\u2019 (score 7-9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 56 HCP [51.8% Hospital Pharmacy; 41.1% Oncology; 3.6% Nursing; and 3.6% Psycho-oncology; mean time in specialty 12.5 (8.0) years] and 10 AOC patients [mean time diagnosis 5.4 (3.0) years] participated in the 1<jats:sup>st<\/jats:sup> round. All PROs achieved consensus regarding their relevance, except dry skin (58.0%). Agreement was reached for PRO-CTCAE to be used to assess fatigue (A:84.9%; F:75.8%), neuropathy (A:92.4%; F:77.3%), diarrhea (A:87.9%; F:88.7%), constipation (A:86.4%; F:75.8%), nausea (A:89.4%; F:75.8%), insomnia (A:81.8%; F:88.7%), abdominal bloating (A:82.2%; F:82.2%) and sexuality (A:78.8%; F:88.6%); EQ-5D to determine patients\u2019 HRQoL (A:87.9%; F:80.3%), pain (A:87.9%; F:75.8%) and mood (A:77.7%; F:85.5%); to assess treatment adherence the Morisky-Green (A:90.9%; F:84.9%) and the dispensing register (A:80.3%; F:80.3%) were chosen. It was agreed to note in the medical record whether the patient\u2019s treatment preferences had been considered during decision-making (A:78.8%; F:78.8%) and to use a 5-point Likert scale to assess treatment satisfaction (A:86.4%; F:86.4%). Panelists agreed (A:92.4%; F: 77.3%) to collect these PROs (1) at the time of diagnosis\/relapse; (2) one month after starting treatment\/change therapeutic strategy; (3) every three months during the 1<jats:sup>st<\/jats:sup>-year of treatment; and later (4) every six months until treatment completion\/change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The consensus reached represents the first step towards including the patient\u2019s perspective in AOC follow-up. The standardized collection of PROs in clinical practice may contribute to optimizing the follow-up of these patients and thus improving the quality of care.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.885910","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T14:46:26Z","timestamp":1652885186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Vicente","family":"Escudero-Vilaplana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Collado-Borrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Diez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Fern\u00e1ndez Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Folguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Gonz\u00e1lez-Cortijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Herrero-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Mart\u00ednez Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rosa","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sanmartin-Fenollera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Vazquez Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Comellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial Ovarian Cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181a3a436","article-title":"Reasons for Improved Survival From Ovarian Cancer in New South Wales, Australia, Between 1980 and 2003: Implication for Cancer Control","volume":"19","author":"Tracey","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"dju128","DOI":"10.1093\/jnci\/dju128","article-title":"Recommended Patient-Reported Core Set of Symptoms and Quality-of-Life Domains to Measure in Ovarian Cancer Treatment Trials","volume":"106","author":"Donovan","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6947-13-6","article-title":"Patient-Centered Medicine and Patient-Oriented Research: Improving Health Outcomes for Individual Patients","volume":"13","author":"Sacrist\u00e1n","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1398088","article-title":"Optimizing Treatment in Recurrent Epithelial Ovarian Cancer","volume":"17","author":"Corrado","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"B8","article-title":"Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-Reported Outcomes to Support Medical Product Labeling Claims: FDA Perspective","volume":"10","author":"Patrick","year":"2007","journal-title":"Value Health"},{"key":"B10","article-title":"Reflection Paper on the Use of Patient Reported Outcome (PRO) Measures in Oncology Studies","year":"2014"},{"key":"B11","article-title":"Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000147","article-title":"Symptom Burden and Outcomes of Patients With Platinum Resistant\/Refractory Recurrent Ovarian Cancer: A Reality Check: Results of Stage 1 of the Gynecologic Cancer Intergroup Symptom Benefit Study","volume":"24","author":"Friedlander","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2016.01.001","article-title":"Developing a Core Set of Patient-Reported Outcomes in Pancreatic Cancer: A Delphi Survey","volume":"57","author":"Gerritsen","year":"2016","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/fampra\/10.1.76","article-title":"The Nominal Group Technique: A Research Tool for General Practice","volume":"10","author":"Gallagher","year":"1993","journal-title":"Family Pract"},{"key":"B16","article-title":"The Nominal Group Technique: A Useful Consensus Methodology in Physiotherapy Research","volume":"3","author":"Potter","year":"2004","journal-title":"New Z J Physiother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000393","article-title":"Using the Delphi Technique to Determine Which Outcomes to Measure in Clinical Trials: Recommendations for the Future Based on a Systematic Review of Existing Studies","volume":"8","author":"Sinha","year":"2011","journal-title":"PloS Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135162","article-title":"Evaluation of Nine Consensus Indices in Delphi Foresight Research and Their Dependency on Delphi Survey Characteristics: A Simulation Study and Debate on Delphi Design and Interpretation","volume":"10","author":"Birko","year":"2015","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining Consensus: A Systematic Review Recommends Methodologic Criteria for Reporting of Delphi Studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725050-00002","article-title":"Health Utilities Using the EQ-5D in Studies of Cancer","volume":"25","author":"Pickard","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000372","article-title":"Incorporating the Patient's Perspective in Outcomes Research","volume":"29","author":"Hsiao","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension. 309","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"B25","volume-title":"Strategies for Overcoming Barriers to the Implementation of Patient-Reported Outcomes Measures","author":"Locklear","year":"2014"},{"key":"B26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s41687-018-0072-3","article-title":"The Facilitators and Barriers to Implementing Patient Reported Outcome Measures in Organisations Delivering Health Related Services: A Systematic Review of Reviews","volume":"2","author":"Foster","year":"2018","journal-title":"J Patient Rep Outcomes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1062860617745986","article-title":"Barriers and Benefits to the Use of Patient-Reported Outcome Measures in Routine Clinical Care: A Qualitative Study","volume":"33","author":"Philpot","year":"2017","journal-title":"Am J Med Quality"},{"key":"B28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/1472-6963-12-431","article-title":"Using Patient Reported Outcome Measures in Health Services: A Qualitative Study on Including People With Low Literacy Skills and Learning Disabilities","volume":"12","author":"Jahagirdar","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s41687-020-00237-2","article-title":"Delphi Survey to Inform Patient-Reported Symptom Monitoring After Ovarian Cancer Treatment","volume":"4","author":"Shearsmith","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30021-8","article-title":"The Increasing Value of Ehealth in the Delivery of Patient-Centred Cancer Care","volume":"21","author":"Penedo","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.885910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T14:46:34Z","timestamp":1652885194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.885910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.885910"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.885910","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"885910"}}